REG - Solvonis Therapeutic - Synthesis of development candidate for SVN-SDN-014

Solvonis TherapeuticsAnnouncement

05/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250605:nRSE5149La&default-theme=true

RNS Number : 5149L  Solvonis Therapeutics PLC  05 June 2025

5 June 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Synthesis of development candidates for SVN-SDN-014 programme

Further to the Company's announcement on 18 March 2025, Solvonis Therapeutics
plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel
medicines for addiction and mental health disorders, provides a progress
update on its preclinical programme, SVN-SDN-014 (the "Programme"), a novel
series of serotonin ("SERT"), dopamine ("DAT"), and noradrenaline ("NET")
modulators in development for trauma-related mental health conditions,
including Post-Traumatic Stress Disorder ("PTSD"). Prior to the Company's
acquisition of Awakn Life Sciences Corp., which completed on 27 May 2025, the
Programme was previously referred to as AWKN-SDN-014.

The Programme aims to develop a new class of medicines for PTSD which affects
an estimated 13 million adults in the United States alone, with the Company
estimating a total affected population of approximately 20 million across the
United States, United Kingdom and key other European markets.

The SVN-SDN-014 series is designed to enhance pro-social behaviour and is
being developed with the aim of delivering an improved safety profile compared
to existing investigational treatments for PTSD. By modulating neurochemical
pathways associated with trust, empathy, and social bonding, the compounds aim
to support patients in rebuilding interpersonal relationships, reducing
isolation, and engaging more effectively in therapy.

The Company has now completed the synthesis of development candidates, marking
the third of seven stages in the SVN-SDN-014 translational development plan.
This latest phase involved the synthesis of a focused set of compounds for
subsequent preclinical characterisation, including pharmacological and
toxicological profiling.

The remaining stages for the programme are as follows:

1.    In-vitro screening for SERT, DAT and NET re-absorption inhibition

2.    In-vitro screening for SERT, DAT and NET release - expected to
complete by the end of July 2025

3.    Pre-clinical animal testing

4.    Lead candidate selection - expected by the end of Q3 2025

Further details of the remaining stages can be found in the Company's
announcement on 18 March 2025.

Anthony Tennyson, Chief Executive Officer of Solvonis, commented: "SVN-SDN-014
represents a novel, mechanism-driven approach to treating PTSD, an area of
significant and persistent clinical need. With candidate synthesis now
complete, we are progressing the programme toward formal lead selection and
IND-enabling studies."

Further updates will be provided as the Programme advances toward regulatory
submission.

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds that target high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programs address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 trials for severe AUD in Europe and the UK. SVN-002 is preparing for a
Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD program leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFIMBTMTMMTIA